Pharmacologic treatment for memory disorder in multiple sclerosis

Are cognitive interventions for Multiple Sclerosis effective and feasible?

“…Pharmacological treatments, including drugs such as donepezil, memantine, rivastigmine, methylphenidate, and l-amphetamine have been examined for their impact on memory, information processing and divided attention (Amato et al, 2013;He et al, 2011). While some positive results have been noted (Krupp et al, 2004) they were often followed by a failure to replicate the results (Amato et al, 2013;Krupp et al, 2011), therefore the impact of such treatments remains to be debatable (He et al, 2011). One exception is L-amphetamine sulfate, which has shown some potential in improving learning and memory in MS (Sumowski et al, 2011).…”

Are cognitive interventions for Multiple Sclerosis effective and feasible?

“…Pharmacological treatments, including drugs such as donepezil, memantine, rivastigmine, methylphenidate, and l-amphetamine have been examined for their impact on memory, information processing and divided attention (Amato et al, 2013;He et al, 2011). While some positive results have been noted (Krupp et al, 2004) they were often followed by a failure to replicate the results (Amato et al, 2013;Krupp et al, 2011), therefore the impact of such treatments remains to be debatable (He et al, 2011). One exception is L-amphetamine sulfate, which has shown some potential in improving learning and memory in MS (Sumowski et al, 2011).…”

Cognitive Dysfunction in Multiple Sclerosis

“…However, up to now there is insufficient evidence of the efficiency of these drugs in MS and their role in the cognitive decline of MS patients is still controversial (Christodoulou et al, 2008), awaiting specifically designed trials allowing longitudinal assessments. As stated in a recent Cochrane review of this subject, until the results of ongoing studies are available, there is no convincing evidence to support pharmacologic intervention as an effective treatment for memory disorder in MS patients (He et al, 2011). …”

Dose-Dependent Role of a New Biotin Compound in Hippocampal Demyelination in Rats

“…It is worth mentioning that most of the MS clinical trials that also used proven disease-modifying drugs do not bring considerable bene ts in cognition and clinical outcomes [23]. Taken up, it is still unclear whether these drugs are effective in the cognitive dysfunction of MS patients [24], suggesting the importance of the results of ongoing MS cognition studies [25]. It is di cult to estimate why cognitive dysfunction responds poorly to any pharmacologic intervention.…”

Are cognitive interventions for Multiple Sclerosis effective and feasible?

“…Pharmacological treatments, including drugs such as donepezil, memantine, rivastigmine, methylphenidate, and l-amphetamine have been examined for their impact on memory, information processing and divided attention (Amato et al, 2013;He et al, 2011). While some positive results have been noted (Krupp et al, 2004) they were often followed by a failure to replicate the results (Amato et al, 2013;Krupp et al, 2011), therefore the impact of such treatments remains to be debatable (He et al, 2011). One exception is L-amphetamine sulfate, which has shown some potential in improving learning and memory in MS (Sumowski et al, 2011).…”

Cognitive Dysfunction in Multiple Sclerosis

“…However, up to now there is insufficient evidence of the efficiency of these drugs in MS and their role in the cognitive decline of MS patients is still controversial (Christodoulou et al, 2008), awaiting specifically designed trials allowing longitudinal assessments. As stated in a recent Cochrane review of this subject, until the results of ongoing studies are available, there is no convincing evidence to support pharmacologic intervention as an effective treatment for memory disorder in MS patients (He et al, 2011). …”

Dose-Dependent Role of a New Biotin Compound in Hippocampal Demyelination in Rats

“…It is worth mentioning that most of the MS clinical trials that also used proven disease-modifying drugs do not bring considerable bene ts in cognition and clinical outcomes [23]. Taken up, it is still unclear whether these drugs are effective in the cognitive dysfunction of MS patients [24], suggesting the importance of the results of ongoing MS cognition studies [25]. It is di cult to estimate why cognitive dysfunction responds poorly to any pharmacologic intervention.…”

Are cognitive interventions for Multiple Sclerosis effective and feasible?

“…Pharmacological treatments, including drugs such as donepezil, memantine, rivastigmine, methylphenidate, and l-amphetamine have been examined for their impact on memory, information processing and divided attention (Amato et al, 2013;He et al, 2011). While some positive results have been noted (Krupp et al, 2004) they were often followed by a failure to replicate the results (Amato et al, 2013;Krupp et al, 2011), therefore the impact of such treatments remains to be debatable (He et al, 2011). One exception is L-amphetamine sulfate, which has shown some potential in improving learning and memory in MS (Sumowski et al, 2011).…”

Cognitive Dysfunction in Multiple Sclerosis

“…However, up to now there is insufficient evidence of the efficiency of these drugs in MS and their role in the cognitive decline of MS patients is still controversial (Christodoulou et al, 2008), awaiting specifically designed trials allowing longitudinal assessments. As stated in a recent Cochrane review of this subject, until the results of ongoing studies are available, there is no convincing evidence to support pharmacologic intervention as an effective treatment for memory disorder in MS patients (He et al, 2011). …”

Dose-Dependent Role of a New Biotin Compound in Hippocampal Demyelination in Rats

“…It is worth mentioning that most of the MS clinical trials that also used proven disease-modifying drugs do not bring considerable bene ts in cognition and clinical outcomes [23]. Taken up, it is still unclear whether these drugs are effective in the cognitive dysfunction of MS patients [24], suggesting the importance of the results of ongoing MS cognition studies [25]. It is di cult to estimate why cognitive dysfunction responds poorly to any pharmacologic intervention.…”